Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preserving blood-brain barrier properties after a metabolic insult in an in vitro model: A role for N-oleoylethanolamide supplementation.

Biochemical pharmacology·2026
Same author

ASGR2 and CLEC12A as Prognostically Relevant C-Type Lectin Hubs in Glioblastoma.

International journal of molecular sciences·2026
Same author

Potential impact of early pharmacological treatment on gene therapy outcomes in AADC deficiency.

Parkinsonism & related disorders·2026
Same author

Brain Metastasis From Anal Canal Squamous Cell Carcinoma: A Rare Case Report and Systematic Review.

Clinical colorectal cancer·2026
Same author

A critical analysis of the global oases mapping.

PeerJ·2026
Same author

Intraoperative Ultrasound in the Management of Rare Lesions Involving the Intradural Extramedullary Spinal Compartment: A Quick, but Effective Helping Hand to Define the Optimal Surgical Strategy.

Cancers·2025

Related Experiment Video

Updated: Jul 5, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
04:36

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

Anemia in renal insufficiency.

Antonio Santoro1

  • 1Division of Nephrology and Dialysis Policlinico S. Orsola-Malpighi, Bologna, Italy.

Reviews in Clinical and Experimental Hematology
|May 9, 2003
PubMed
Summary

Anemia in renal failure significantly impacts quality of life. Recombinant human erythropoietin (rHuEPO) treats anemia, but some patients resist treatment, often due to iron deficiency.

Area of Science:

  • Nephrology
  • Hematology
  • Internal Medicine

Background:

  • Anemia in renal failure severely affects patient quality of life and contributes to left ventricular hypertrophy.
  • Reduced glomerular filtration rate leads to inadequate erythropoietin (EPO) production, the primary cause of anemia in these patients.
  • EPO regulates erythroid progenitor growth and survival.

Purpose of the Study:

  • To review the impact of anemia in chronic renal failure.
  • To discuss the role and efficacy of recombinant human erythropoietin (rHuEPO) in treating renal anemia.
  • To highlight challenges in EPO treatment, such as resistance, and emerging research directions.

Main Methods:

  • Literature review of studies on anemia in chronic renal failure.
  • Analysis of the mechanism of action and clinical application of rHuEPO.

More Related Videos

Noninvasive and Invasive Renal Hypoxia Monitoring in a Porcine Model of Hemorrhagic Shock
07:48

Noninvasive and Invasive Renal Hypoxia Monitoring in a Porcine Model of Hemorrhagic Shock

Published on: October 28, 2022

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Related Experiment Videos

Last Updated: Jul 5, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
04:36

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

Noninvasive and Invasive Renal Hypoxia Monitoring in a Porcine Model of Hemorrhagic Shock
07:48

Noninvasive and Invasive Renal Hypoxia Monitoring in a Porcine Model of Hemorrhagic Shock

Published on: October 28, 2022

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

  • Examination of factors contributing to EPO resistance and current research on anemia prevention.

    • Main Results:

    • Recombinant human erythropoietin (rHuEPO) has revolutionized anemia treatment in chronic renal failure, with most patients responding well.
    • A significant minority (5-10%) of patients exhibit resistance to rHuEPO therapy.
    • Iron deficiency is identified as the most common cause of EPO resistance.
    • Ongoing research focuses on preventing renal anemia and re-evaluating target hemoglobin levels.

    Conclusions:

    • rHuEPO is a cornerstone therapy for anemia in chronic renal failure, significantly improving patient outcomes.
    • Addressing iron deficiency is crucial for optimizing rHuEPO treatment efficacy.
    • Further research into anemia prevention and personalized treatment targets is warranted for pre-dialysis and dialysis patients.